Second-Line Therapy After VEGF Targeted Therapy in Metastatic Renal Cancer: A Law of Diminishing Returns

被引：6
|
作者：
Powles, Thomas [1 ]
机构：
[1] QueenMary Univ London, Barts Canc Inst, St Bartholomews Hosp, London, England
来源：
CLINICAL GENITOURINARY CANCER | 2012年 / 10卷 / 02期
关键词：
CELL CARCINOMA; SUNITINIB; BIOMARKER;
D O I：
10.1016/j.clgc.2012.04.001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：67 / 68
页数：2
相关论文
共 50 条
  • [1] Optimization of second-line targeted therapy for metastatic renal cell carcinoma cancer after use of VEGF receptor - tyrosine kinase inhibitors (literature review)
    Sarkor, R. V.
    [J]. ONKOUROLOGIYA, 2012, 8 (04): : 22 - 26
  • [2] The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients
    Al-Marrawi, Mhd Y.
    Rini, Brian I.
    Harshman, Lauren C.
    Bjarnason, Georg
    Wood, Lori
    Vaishampayan, Ulka
    MacKenzie, Mary
    Knox, Jennifer J.
    Agarwal, Neeraj
    Al-Harbi, Hulayel
    Kollmannsberger, Christian
    Tan, Min-Han
    Rha, Sun Young
    Donskov, Frede N.
    North, Scott
    Choueiri, Toni K.
    Heng, Daniel Y.
    [J]. TARGETED ONCOLOGY, 2013, 8 (03) : 203 - 209
  • [3] The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients
    Mhd Y. Al-Marrawi
    Brian I. Rini
    Lauren C. Harshman
    Georg Bjarnason
    Lori Wood
    Ulka Vaishampayan
    Mary MacKenzie
    Jennifer J. Knox
    Neeraj Agarwal
    Hulayel Al-Harbi
    Christian Kollmannsberger
    Min-Han Tan
    Sun Young Rha
    Frede N. Donskov
    Scott North
    Toni K. Choueiri
    Daniel Y. Heng
    [J]. Targeted Oncology, 2013, 8 : 203 - 209
  • [4] Second-line systemic therapy for the treatment of metastatic renal cell cancer
    Kruck, Stephan
    Bedke, Jens
    Kuczyk, Markus A.
    Merseburger, Axel S.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (06) : 777 - 785
  • [5] Second-line therapy for metastatic colorectal cancer
    Price, Timothy J.
    [J]. LANCET ONCOLOGY, 2015, 16 (05): : 476 - 477
  • [6] Second-line therapy of metastatic bladder cancer
    Retz, M.
    Bokemeyer, C.
    [J]. ONKOLOGE, 2012, 18 (11): : 1018 - 1022
  • [7] Individual approach in choosing second-line targeted therapy for metastatic renal cell carcinoma
    Alekseev, B. Ya.
    Shevchuk, I. M.
    Kaprin, A. D.
    [J]. ONKOUROLOGIYA, 2018, 14 (02): : 68 - 78
  • [8] Metastatic Colorectal Cancer Second-line Therapy with anti-VEGF (R) Concept
    Eimer, Martina
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (12) : 793 - 793
  • [9] Everolimus as second-line therapy for metastatic renal cell carcinoma (mRCC) after one previous VEGF-targeted therapy: Final results of the noninterventional change study
    Goebell, Peter J.
    Kube, Ulrich
    Staehler, Michael
    Doehn, Christian
    Steiner, Thomas
    Kindler, Manfred
    Herrmann, Edwin
    Janssen, Jan
    Weikert, Steffen
    Scheffler, Michael Thomas
    Schmitz, Joerg
    Overkamp, Friedrich
    Guderian, Gernot
    Albrecht, Michael
    Bergmann, Lothar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [10] The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts)
    Al-Marrawi, M. Y.
    Rini, B. I.
    Harshman, L. C.
    Bjarnason, G. A.
    Wood, L.
    Vaishampayan, U. N.
    MacKenzie, M. J.
    Knox, J. J.
    Agarwal, N.
    Kollmannsberger, C. K.
    Tan, M.
    Rha, S. Y.
    Donskov, F.
    North, S. A.
    Choueiri, T. K.
    Heng, D. Y. C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345